Orthopedic biomaterials market seen reaching $49.5 billion by 2035

Market Research Future projects the global orthopedic biomaterials market will grow from $25.70 billion in 2026 to $49.50 billion by 2035, driven by aging populations, osteoarthritis, robotic surgery adoption and additive manufacturing. The forecast also points to faster growth in ceramics, orthobiologics and biodegradable materials as hospitals and outpatient centers shift toward precision implants and value-based care.

Why it matters: - The orthopedic biomaterials market is moving from a niche implant category to a larger, tech-enabled healthcare segment tied to joint reconstruction, spinal fusion and early intervention care. - Demand is being reinforced by aging populations, higher osteoarthritis burden, robotic-assisted surgery and patient-matched implant manufacturing. - The forecast implies more procedure volume, more precision implant use and more spending pressure on payers and health systems through 2035.

What happened: - Market Research Future projects the global orthopedic biomaterials market will rise from $25.70 billion in 2026 to $49.50 billion by 2035. - The forecast implies a 7.55% compound annual growth rate from 2026 through 2035. - The market base was estimated at $23.90 billion in 2025. - The report was published July 17, 2026. - A free sample and full report are available from Market Research Future.

The details: - The market’s growth is being driven by three main forces: an aging population and osteoarthritis burden, broader robotic-assisted surgery adoption and additive manufacturing scale-up. - The WHO estimates about 500 million people worldwide have osteoarthritis, and that figure is expected to rise 40% by 2035. - The American Academy of Orthopaedic Surgeons projects total joint arthroplasties in the U.S. will exceed 4 million annually by 2030. - The FDA granted 78 Breakthrough Device Designations to orthopedic products from 2020 to 2025. - The median review time for those products was about 5.8 months, versus 11.2 months for standard 510(k) submissions. - Companies invested more than $3.5 billion in patient-specific implant R&D from 2022 to 2025. - Medicare joint replacement spending in the U.S. exceeds $12 billion a year as of 2024. - CMS estimates that spending will grow 6% annually over the next 10 years. - Robotic platforms such as Zimmer Biomet’s ROSA and Stryker’s Mako grew from fewer than 1,500 installed systems in 2020 to more than 5,200 worldwide by 2025. - AI-driven surgical planning tools can auto-segment CT scans, recommend implant size and alignment, and reduce operative time by 10 to 15 minutes per case in early clinical trials. - Machine-learning models trained on more than 2 million orthopedic imaging datasets can detect joint degeneration 18 to 24 months earlier than conventional radiographic assessment. - Metal 3-D printing now supports more than 150,000 spinal cages and acetabular cups annually across major OEMs. - Porous lattice implant designs are associated with 15% to 25% better osseointegration rates than traditionally machined surfaces, based on clinical registry data from the National Joint Registry of England and Wales. - CMS bundled-payment models and European reimbursement systems are pushing hospitals toward value-based orthopedic purchasing. - Preventing a single revision joint replacement saves payers about $15,000 to $25,000 per patient in European data. - The report says these economics are shifting procurement toward bioactive ceramic bearings and cross-linked polyethylene liners.

Between the lines: - The market is being pulled by structural healthcare demand, not discretionary spending, which makes the growth profile more durable than many medical device categories. - Robotic surgery and additive manufacturing are changing what hospitals buy, not just how surgeons operate. - The strongest upside appears to be in premium, precision-oriented products, while pooled procurement and commoditization may pressure margins in lower-end materials. - The report also signals that reimbursement policy may matter as much as clinical innovation in determining which biomaterials win share.

What's next: - The report expects precision orthopedic theranostics to become a core workflow by 2030. - It says about 30% of primary joint replacements could use AI-assisted preoperative planning by 2030. - Start-ups have raised more than $800 million in venture funding for orthopedic decision-support tools since 2023. - Growth is likely to remain strongest in Asia-Pacific, where the report forecasts an 8.60% CAGR from 2026 to 2035. - North America remains the largest regional market, while Europe stays the second largest and the Middle East and Africa continue as an emerging opportunity.

The bottom line: - Orthopedic biomaterials are shifting toward a larger, faster-growing market built around aging patients, robotic surgery and customized implants.